ContraFect Corp (NASDAQ:CFRX) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 392,500 shares, an increase of 16.5% from the June 30th total of 337,000 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 514,900 shares, the days-to-cover ratio is presently 0.8 days.
CFRX has been the subject of several research analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $1.50 target price on shares of ContraFect in a research report on Wednesday, May 15th. ValuEngine upgraded ContraFect from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Maxim Group assumed coverage on ContraFect in a research note on Tuesday, June 11th. They set a “buy” rating for the company.
Shares of CFRX stock traded down $0.01 on Thursday, hitting $0.39. 161,117 shares of the stock were exchanged, compared to its average volume of 922,073. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $32.31 million, a price-to-earnings ratio of -1.05 and a beta of 0.07. ContraFect has a one year low of $0.35 and a one year high of $2.63. The firm has a 50 day moving average price of $0.47.
Several hedge funds have recently bought and sold shares of the company. Oracle Investment Management Inc. grew its stake in shares of ContraFect by 13.1% during the 2nd quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after acquiring an additional 735,450 shares during the period. White Pine Capital LLC boosted its stake in ContraFect by 207.9% in the 1st quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock worth $361,000 after purchasing an additional 612,700 shares during the period. SG Americas Securities LLC bought a new position in ContraFect in the 2nd quarter worth about $343,000. Trellus Management Company LLC bought a new position in ContraFect in the 2nd quarter worth about $295,000. Finally, Geode Capital Management LLC boosted its stake in ContraFect by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock worth $578,000 after purchasing an additional 29,009 shares during the period. Institutional investors own 39.19% of the company’s stock.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
See Also: The mechanics of the bid-ask spread in trading
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.